Highly sensitive detection of GATA1 mutations in patients with myeloid leukemia associated with Down syndrome by combining Sanger and targeted next generation sequencing. Issue 3 (21st October 2019)

• Record Type: Journal Article
• Authors: Terui, Kiminori; Toki, Tsutomu; Taga, Takashi; Iwamoto, Shotaro; Miyamura, Takako; Hasegawa, Daisuke; Moritake, Hiroshi; Hama, Asahito; Nakashima, Kentaro; Kanezaki, Rika; Kudo, Ko; Saito, Akiko M.; Horibe, Keizo; Adachi, Souichi; Tomizawa, Daisuke; Ito, Etsuro
• Is Part Of: Genes, chromosomes & cancer. Volume 59:Issue 3(2020)
• Page Start: 160
• Page End: 167
• Publication Date: 2019-10-21
• Subjects: down syndrome -- GATA1 -- mutation -- myeloid leukemia -- next generation sequencing -- sanger sequencing; Cancer -- Genetic aspects -- Periodicals; 616.994042
• DOI: 10.1002/gcc.22816
• Languages: English
• ISSNs: 1045-2257

Abstract

Abstract: Myeloid leukemia associated with Down syndrome (ML‐DS) is characterized by a predominance of acute megakaryoblastic leukemia, the presence of GATA1 mutations and a favorable outcome. Because DS children can also develop conventional acute myeloid leukemia with unfavorable outcome, detection of GATA1 mutations is important for diagnosis of ML‐DS. However, myelofibrosis and the significant frequency of dry taps have hampered practical screening of GATA1 mutations using bone marrow (BM) samples. In response to those problems, 82 patients were enrolled in the Japanese Pediatric Leukemia/Lymphoma Study Group AML‐D11 study. GATA1 mutations were analyzed by Sanger sequencing (SS) using genomic DNA (gDNA) from BM and cDNA from peripheral blood (PB) followed by targeted next‐generation sequencing (NGS) using pooled diagnostic samples. BM and PB samples were obtained from 71 (87%) and 82 (100%) patients, respectively. GATA1 mutations were detected in 46 (56%) and 58 (71%) patients by SS using BM gDNA and PB cDNA, respectively. Collectively, GATA1 mutations were identified in 73/82 (89%) patients by SS. Targeted NGS detected GATA1 mutations in 74/82 (90%) patients. Finally, combining the results of SS with those of targeted NGS, GATA1 mutations were identified in 80/82 (98%) patients. These results indicate that SS using BM gDNA and PB cDNA is a rapid and useful method for screening for GATA1 mutations in ML‐DS patients. Thus, a combination of SS and targeted NGS is a sensitive and useful method to evaluate the actual incidence and clinical significance of GATA1 mutations in ML‐DS patients.